[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553530":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":11,"locations":17,"responsibleParty":32,"collaborators":36,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":7,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Paolo Manzoni","OTHER",null,[9],{"type":6,"name":10,"description":10,"armGroupLabels":7,"otherNames":7},"observational study",[12],{"name":13,"role":14,"phone":15,"phoneExt":7,"email":16},"Paolo Manzoni, Professor","CONTACT","+39 01515156906","paolo.manzoni@aslbi.piemonte.it",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Ospedale degli Infermi - ASL BI","RECRUITING","Ponderano","BI","13875","Italy","IT",{"type":27,"coordinates":28},"Point",[29,30],8.05592,45.53846,{"lat":30,"lon":29},{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Paolo Manzoni Study Group","Principal Investigator, Head of Department of Maternal, Neonatal and Infant Medicine, Associate Professor",[37],{"name":38,"class":6},"Università degli Studi del Piemonte Orientale Amedeo Avogadro","100553530","levels-of-visfatinnampt-in-human-milk-100553530",false,"NCT06487286","Levels of Visfatin\u002FNAMPT in Human Milk","Levels of Visfatin\u002FNAMPT in Human Milk.VISFAMILK","VISFAMILK","Inclusion Criteria:\n\n* Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities\n* Maternal hospitalization\n* Acquisition of the informed consent form signed by the patient\n\nExclusion Criteria:\n\n* Refusal of the patient to participate in the study\n* Presence of hypogalactia or agalactia in the patient","ALL",{"count":49,"type":50},30,"ESTIMATED","OBSERVATIONAL","Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic\u002Fpredictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.",[54,55],"Visfatin Levels in Maternal Milk Samples","Birth Weight",[57,58,59],"Newborns","Visfatin","Breastfeeding","2024-11-12",{"date":62,"type":63},"2024-11-14","ACTUAL",{"date":65,"type":63},"2024-10-24",{"date":67,"type":50},"2025-04-23",{"name":34,"class":6},1]